Neurocrine Biosciences Inc vs Solaredge Technologies Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Solaredge Technologies Inc trades at $50.3 (market cap $2.96B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.9× Solaredge Technologies Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SEDG | |
|---|---|---|
Market Cap | $17.40B | $2.96B |
Sector | Health | Technology |
52-Week High | $180.55 | $78.51 |
52-Week Low | $123.10 | $24.42 |
Enterprise Value | $16.49B | $2.89B |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →